AstraZeneca PLC (AZN.L)
|Market Cap (Mil.):||£55,027.70|
|Shares Outstanding (Mil.):||1,262.56|
- Pfizer Inc , which in May abandoned its $118 billion bid for AstraZeneca Plc , on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. | Video
(Adds CEO, CFO, analyst comments, details on experimental drugs, paragraphs 4-15)
(Adds Pfizer, Nobel Biocare, Edison, Millhouse Capital, Bank of Cyprus)
- Pfizer Inc , which in May abandoned its $118 billion bid to buy AstraZeneca Plc , on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals.
July 29 - Pfizer Inc : * CEO, in investor conference call, says feels current company strategy "right on" despite revenue growth
July 29 - Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.
BEIJING, July 28 - Microsoft Corp appears to be the latest U.S. company targeted by China for anti-trust investigation after government officials paid sudden visits to the software firm's Chinese offices on Monday.
LONDON - AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.
LONDON, July 28 - AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.
NEW YORK - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
"The Economy Matters" Report for AZN: the economy's impact on AZN's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports
AstraZeneca PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.